About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Insulin glargine U-300
Insulin glargine U-300
- Company
- Marmara University
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Oct 14, 2026
Trial details
-
Completed NCT NCT02227212
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Not yet reported Sanofi 40 participants Est. completion 2014-11 7 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02401243
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Not yet reported Sanofi 253 participants Est. completion 2016-02 25 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02585674
Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo
Not yet reported Sanofi 151 participants Est. completion 2016-11 19 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02688933
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Not yet reported Sanofi 638 participants Est. completion 2017-06-19 100 sitesOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT02855684
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
Not yet reported Sanofi 604 participants Est. completion 2018-08-06 54 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02954692
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Not yet reported Sanofi 112 participants Est. completion 2017-12-22 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02967211
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
Not yet reported Sanofi 609 participants Est. completion 2017-10-20 118 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02967224
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
Not yet reported Sanofi 705 participants Est. completion 2017-10-16 128 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02967237
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Not yet reported Sanofi 136 participants Est. completion 2017-07-24 85 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03389490
Toujeo Versus NPH Self-titration Study
Not yet reported Elaine Chow 50 participants Est. completion 2020-05-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03406000
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
Not yet reported Sanofi 170 participants Est. completion 2019-02-04 11 sitesOther conditions: Type I Diabetes MellitusView official trial listing → -
Completed NCT NCT03703869
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Sanofi 4589 participants Est. completion 2020-02-24 388 sitesOther conditions: DiabetesView official trial listing → -
Completed NCT NCT03760991
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
Not yet reported Sanofi 372 participants Est. completion 2020-09-23 14 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT04692415
Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors
Not yet reported University of Split, School of Medicine 25 participants Est. completion 2019-06-27 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04980027
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Not yet reported Sanofi 228 participants Est. completion 2022-12-23 2 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT05002933
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
Not yet reported Sanofi 570 participants Est. completion 2023-02-24 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05036876
Degludec Glargine U300 Hospital Study
Not yet reported Medanta, The Medicity, India 220 participants Est. completion 2022-03-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07786571
Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency
Not yet reported Sun Yat-sen University 206 participants Est. completion 2029-07-01 1 siteType 2 diabetesChronic kidney disease Other conditions: Chronic Renal Insufficiency, Glucose HomeostasisView official trial listing → -
Completed NCT NCT07872475
Randomized Transition to Gla-300 in Pediatric Type 1 Diabetes: CGM-Derived Outcomes
Not yet reported Marmara University 71 participants Est. completion 2026-05-01 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.